- Home
- FNWD vs KLRS Comparison
FNWD vs KLRS Comparison
Compare FNWD & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWD
- KLRS
- Stock Information
- Founded
- FNWD 1994
- KLRS 2019
- Country
- FNWD United States
- KLRS United States
- Employees
- FNWD N/A
- KLRS N/A
- Industry
- FNWD Savings Institutions
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FNWD Finance
- KLRS Health Care
- Exchange
- FNWD Nasdaq
- KLRS Nasdaq
- Market Cap
- FNWD 133.3M
- KLRS 129.0M
- IPO Year
- FNWD N/A
- KLRS N/A
- Fundamental
- Price
- FNWD $28.25
- KLRS $2.50
- Analyst Decision
- FNWD Buy
- KLRS Buy
- Analyst Count
- FNWD 1
- KLRS 1
- Target Price
- FNWD $34.00
- KLRS N/A
- AVG Volume (30 Days)
- FNWD 29.9K
- KLRS 39.9K
- Earning Date
- FNWD 07-23-2025
- KLRS 08-15-2025
- Dividend Yield
- FNWD 1.69%
- KLRS N/A
- EPS Growth
- FNWD N/A
- KLRS N/A
- EPS
- FNWD 0.78
- KLRS N/A
- Revenue
- FNWD $61,430,000.00
- KLRS N/A
- Revenue This Year
- FNWD N/A
- KLRS N/A
- Revenue Next Year
- FNWD $6.97
- KLRS N/A
- P/E Ratio
- FNWD $36.42
- KLRS N/A
- Revenue Growth
- FNWD N/A
- KLRS N/A
- 52 Week Low
- FNWD $24.54
- KLRS $2.28
- 52 Week High
- FNWD $33.50
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- FNWD 44.44
- KLRS N/A
- Support Level
- FNWD $27.16
- KLRS N/A
- Resistance Level
- FNWD $28.80
- KLRS N/A
- Average True Range (ATR)
- FNWD 0.82
- KLRS 0.00
- MACD
- FNWD 0.04
- KLRS 0.00
- Stochastic Oscillator
- FNWD 44.67
- KLRS 0.00
About FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.